For the Inventor, By the Inventor

Enter assignee name

Pembroke, Bermuda

Celgene Car LLC

Calculating rank

USPTO Granted Patents = 44

% Expired Patents = 6.8

CIPO Patents = 1

EPO Patents = 10

Forward Citations = 242

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Deqiang Niu (29 out of 83 patents)

Juswinder Singh (28 out of 68 patents)

Russell Colyn Petter (28 out of 82 patents)

4. Lixin Qiao (13 out of 40 patents)

5. Joseph John McDonald (12 out of 14 patents)

6. Zhendong Zhu (12 out of 20 patents)

7. Hormoz Mazdiyasni (11 out of 19 patents)

8. Kwangho Lee (10 out of 28 patents)

9. Richland Wayne Tester (9 out of 30 patents)

10. John Malona (9 out of 11 patents)

11. Arthur F Kluge (8 out of 96 patents)

12. Alexander L Ruchelman (6 out of 56 patents)

13. William Frederick Westlin, Iii (6 out of 15 patents)

14. Yike Ni (6 out of 7 patents)

15. Chittari Pabba (6 out of 8 patents)

Core Competencies:

MK2 Inhibitors

ERK Inhibitors

Heteroaryl Compounds

Pyrimidine Derivatives

Protein Kinase

Covalent Modification

EGFR Inhibitors

HCV Protease Inhibitors

Solid Forms

Deuterated Analogs

Ligand-Directed

Substituted Compounds

44 patents: Sort by Forward Citations

1. 11655257 - MK2 inhibitors, synthesis thereof, and intermediates thereto (2023-05-23),

2. 11629153 - Forms and compositions of a MK2 inhibitor (2023-04-18),

3. 11584757 - MK2 inhibitors and uses thereof (2023-02-21),

4. 11542492 - Ligand-directed covalent modification of protein (2023-01-03),

5. 11351168 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2022-06-07),

6. 11292772 - Salts of an epidermal growth factor receptor kinase inhibitor (2022-04-05),

7. 11230551 - Deuterated analogs of MK2 inhibitors and uses thereof (2022-01-25),

8. 11124525 - Heteroaryl compounds useful as MK2 inhibitors (2021-09-21),

9. 11098061 - MK2 inhibitors and uses thereof (2021-08-24),

10. 11098057 - 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof (2021-08-24),

11. 11096942 - Heterocyclic compounds and uses thereof (2021-08-24),

12. 10946016 - Solid forms of an epidermal growth factor receptor kinase inhibitor (2021-03-16),

13. 10894796 - MK2 inhibitors, synthesis thereof, and intermediates thereto (2021-01-19),

14. 10882867 - Forms and compositions of a MK2 inhibitor (2021-01-05),

15. 10828300 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2020-11-10),

Company Overview

Celgene Car LLC, based in Pembroke, specializes in the development of innovative therapeutic solutions targeting various protein kinases. The company focuses on advanced research in MK2 inhibitors, EGFR kinase inhibitors, and ERK inhibitors, among other areas. By leveraging heteroaryl compounds and pyrimidines, Celgene Car aims to create novel treatments that utilize covalent modification and deuterated analogs, contributing to the evolving landscape of targeted therapies in oncology and related fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

44 Patents

#1 in Pembroke

#18 in Bermuda

#15,787 in the World

Pembroke, Bermuda

Celgene Car LLC

Forward Citations = 242

53 inventors:

Deqiang Niu (29 out of 83 patents)

Juswinder Singh (28 out of 68 patents)

Russell Colyn Petter (28 out of 82 patents)

4. Lixin Qiao (13 out of 40 patents)

5. Joseph John McDonald (12 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Celgene Car LLC. Retrieved from https://idiyas.com/company/celgene-car

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…